This exploratory analysis assessed whether plasma biomarkers predict the response to switching from phosphodiesterase type 5 inhibitors (PDE5is) to the soluble guanylate cyclase stimulator riociguat in patients with pulmonary arterial hypertension. Selected biomarkers at baseline and their changes to Week 24 were evaluated in patients with and without a favorable response to riociguat in two trials: RESPITE, in which patients with an inadequate response to PDE5i were switched to riociguat; and REPLACE, in which patients at intermediate risk of 1-year mortality despite a PDE5i were randomized to remain on PDE5i or were switched to riociguat. A response was defined as absence of clinical worsening and at least two of the following criteria: 6-min walk distance increase by 10% or
- Klinger, J. R.
- Al-Hiti, H.
- Chang, S. A.
- Chang, H. J.
- Ghofrani, H. A.
- Grünig, E.
- Hoeper, M. M.
- Jansa, P.
- Ota-Arakaki, J.
- Pulido, T.
- Simonneau, G.
- Vizza, C. D.
- Rahner, C.
- Meier, C.
- Meyer, G.
Keywords
- risk assessment
- soluble guanylate cyclase stimulators
- treatment guidelines
